Medicare Enrolled
Dr. Minesh Patel, MD
Hematology & Oncology · Newnan, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Patel from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Patel?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Patel
Dr. Minesh Patel is a hematology & oncology specialist in Newnan, GA, with 16 years of NPI registration. Based on federal Medicare data, Dr. Patel performed 189,651 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Patel received a total of $2,447 from 41 pharmaceutical and/or device companies across 119 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Patel is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years of NPI registration
▲ Top 1% volume in GA
$2,447 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗189,651
Medicare services
Top 1% in GA for hematology & oncology
Not available
Unique patients (not deduplicated)
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection, 1 microgram An injection of filgrastim, a medication that stimulates the production of white blood cells. This code specifically covers the brand-name drug and excludes biosimilar versions. |
45,241 | $1 | $2 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
29,000 | $2 | $10 |
| Pembrolizumab injection (Keytruda) | 24,800 | $41 | $110 |
| Cemiplimab injection, 1 mg This code represents the administration of a 1 mg dose of cemiplimab, a medication delivered via injection. |
24,780 | $20 | $70 |
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
21,000 | $1 | $3 |
| Denosumab injection (Prolia/Xgeva) | 13,260 | $18 | $44 |
| Paclitaxel chemotherapy injection | 10,500 | $0 | $0 |
| Iron infusion (Monoferric) | 5,300 | $16 | $65 |
| Bevacizumab biosimilar injection, 10 mg An injection of bevacizumab-awwb, a biosimilar medication, administered in a 10 mg dose. |
3,060 | $21 | $150 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,385 | $0 | $0 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,486 | $8 | $27 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,300 | $1 | $5 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
881 | $60 | $168 |
| Pegfilgrastim injection, 0.5 mg An injection of pegfilgrastim, a medication that stimulates the production of white blood cells. This specific code applies to the brand-name drug and excludes biosimilar versions. |
840 | $73 | $450 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
814 | $10 | $60 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
630 | $89 | $525 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
508 | $11 | $82 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
487 | $2 | $10 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
400 | $20 | $118 |
| Injection, granisetron hydrochloride, 100 mcg | 360 | $0 | $1 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
317 | $1 | $6 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
269 | $91 | $260 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
184 | $1 | $2 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
180 | $44 | $250 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
162 | $24 | $126 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 154 | $128 | $350 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
147 | $42 | $235 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
147 | $1 | $3 |
| Urinalysis, manual A manual laboratory examination of a urine sample to check for various substances and cells. |
118 | $3 | $15 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
112 | $20 | $131 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
92 | $58 | $172 |
| Injection, triptorelin pamoate, 3.75 mg | 92 | $281 | $1,000 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
85 | $14 | $90 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 78 | $338 | $1,325 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
71 | $38 | $218 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
70 | $74 | $304 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
58 | $115 | $429 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
55 | $9 | $97 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
38 | $31 | $50 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
33 | $1 | $5 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
31 | $68 | $90 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
31 | $96 | $326 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
30 | $22 | $194 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
26 | $2 | $5 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
14 | $129 | $376 |
| Intravenous drug injection A procedure involving the administration of a medication or substance directly into a vein. |
13 | $26 | $155 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
12 | $127 | $439 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
14.7% high complexity
83.5% medium
1.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,447
Total received (2018-2024)
Avg $350/year across 7 years
Bottom 42% in GA for hematology & oncology
41
Companies
119
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$566
2023
$375
2022
$178
2021
$200
2020
$256
2019
$400
2018
$472
Payments by company (2024)
Novartis Pharmaceuticals Corporation
$129
ABBVIE INC.
$84
Regeneron Healthcare Solutions, Inc.
$71
BeiGene USA, Inc.
$68
Stemline Therapeutics Inc.
$51
AstraZeneca Pharmaceuticals LP
$31
Astellas Pharma US Inc
$24
GENZYME CORPORATION
$23
SpringWorks Therapeutics, Inc.
$23
PFIZER INC.
$19
Eisai Inc.
$17
ADC Therapeutics America, Inc.
$14
Janssen Biotech, Inc.
$13
Top 3 companies account for 50.1% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$350
Bayer HealthCare Pharmaceuticals Inc.
$171
Amgen Inc.
$157
Genentech USA, Inc.
$151
Janssen Biotech, Inc.
$144
ABBVIE INC.
$135
Incyte Corporation
$100
BeiGene USA, Inc.
$93
Regeneron Healthcare Solutions, Inc.
$91
Merck Sharp & Dohme Corporation
$91
Astellas Pharma US Inc
$87
SOBI, INC
$70
Stemline Therapeutics Inc.
$65
Pharmacyclics LLC, An AbbVie Company
$61
Daiichi Sankyo Inc.
$54
PFIZER INC.
$50
Merck Sharp & Dohme LLC
$48
Seagen Inc.
$47
EISAI INC.
$36
Seattle Genetics, Inc.
$35
AstraZeneca Pharmaceuticals LP
$31
Kite Pharma, Inc.
$30
Eisai Inc.
$30
McKesson Specialty Care Distribution, LLC
$29
Pharmacyclics LLC, an AbbVie Company
$27
Gilead Sciences, Inc.
$23
Janssen Pharmaceuticals, Inc
$23
GENZYME CORPORATION
$23
SpringWorks Therapeutics, Inc.
$23
E.R. Squibb & Sons, L.L.C.
$17
AbbVie, Inc.
$16
Dova Pharmaceuticals
$16
Boehringer Ingelheim Pharmaceuticals, Inc.
$16
ADC Therapeutics America, Inc.
$14
Mylan Pharmaceuticals Inc.
$14
Alexion Pharmaceuticals, Inc.
$14
Bayer Healthcare Pharmaceuticals Inc.
$13
GlaxoSmithKline, LLC.
$13
Lilly USA, LLC
$13
Octapharma USA, Inc.
$12
Sun Pharmaceutical Industries Inc.
$12
Top 3 companies account for 27.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · BOSULIF · BRUKINSA · CABLIVI · DARZALEX · Doptelet · ENHERTU · EPKINLY · Enhertu · Fulphila · GAZYVA · GLYXAMBI · Gazyva · Herceptin · IMBRUVICA · INLYTA · Imbruvica · JEMPERLI · KEYTRUDA · KISQALI · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · Neulasta · Nubeqa · ODOMZO · OGSIVEO · Orserdu · PANZYGA · PIQRAY · PROMACTA · Padcev · Perjeta · SCEMBLIX · SUTENT · Stivarga · TEVIMBRA · TUKYSA · ULTOMIRIS · VENCLEXTA · VERZENIO · XARELTO · XOSPATA · XTANDI · Xofigo · Yescarta
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
21
County median income
$94,142
Nearest hospital to ZIP centroid (approximate)
PIEDMONT NEWNAN HOSPITAL, INC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Patel is a mixed practice specialist, with above-average Medicare volume (top 1% in GA), with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Patel experienced with filgrastim injection, 1 microgram?
Based on Medicare claims data, Dr. Patel performed 45,241 filgrastim injection, 1 microgram services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Patel receive payments from pharmaceutical companies?
Yes. Dr. Patel received a total of $2,447 from 41 companies across 119 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Patel's costs compare to other hematology & oncology specialists in Newnan?
Dr. Patel's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Patel) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Newnan
Browse hematology & oncology specialists in Newnan ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in GA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in GA
Which GA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Bayer HealthCare Pharmaceuticals Inc. Payments to Doctors
See all physicians who received payments from Bayer HealthCare Pharmaceuticals Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology